Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Virginia O Volpe

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Therapeutic Advances in Hematology|January 28, 2021
Treatment options for lower-risk myelodysplastic syndromes. Where are we now?Virginia O Volpe, Rami S Komrokji
Clinical Lymphoma, Myeloma & Leukemia|September 21, 2021
Myelodysplastic Syndromes: A New DecadeVirginia O Volpe, Guillermo Garcia-Manero, Rami S Komrokji
Clinical Lymphoma, Myeloma & Leukemia|January 22, 2023
SOHO State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic SyndromesVirginia O Volpe, Guillermo Garcia-Manero, Rami S Komrokji
Journal of the American Academy of Dermatology|July 17, 2017
The new paradigm of systemic therapies for metastatic melanomaVirginia O Volpe, Daniel M Klufas, Upendra Hegde, et al.
British Journal of Haematology|June 24, 2022
Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromesVirginia O Volpe, Najla Al Ali, Onyee Chan, et al.
Annals of Hematology|September 7, 2024
Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemiaAkriti G Jain, Virginia O Volpe, Chen Wang, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 28, 2024
Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and OutcomesLuis E Aguirre, Akriti Jain, Somedeb Ball, et al.
Blood Advances|September 25, 2024
Myeloid clonal hematopoiesis of indeterminate potential in patients with chronic lymphocytic leukemiaAbi Vijenthira, Virginia O Volpe, Aswin Sekar, et al.
Leukemia Research|November 8, 2021
MYC overexpression is associated with an early disease progression from MDS to AMLDavid Gajzer, Constantine N Logothetis, David A Sallman, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemiaEmma-Jayne Minihane, Leah Krotee, Jason Wu, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Therapeutic Advances in Hematology|January 28, 2021
Treatment options for lower-risk myelodysplastic syndromes. Where are we now?Virginia O Volpe, Rami S Komrokji
Clinical Lymphoma, Myeloma & Leukemia|September 21, 2021
Myelodysplastic Syndromes: A New DecadeVirginia O Volpe, Guillermo Garcia-Manero, Rami S Komrokji
Clinical Lymphoma, Myeloma & Leukemia|January 22, 2023
SOHO State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic SyndromesVirginia O Volpe, Guillermo Garcia-Manero, Rami S Komrokji
Journal of the American Academy of Dermatology|July 17, 2017
The new paradigm of systemic therapies for metastatic melanomaVirginia O Volpe, Daniel M Klufas, Upendra Hegde, et al.
British Journal of Haematology|June 24, 2022
Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromesVirginia O Volpe, Najla Al Ali, Onyee Chan, et al.
Annals of Hematology|September 7, 2024
Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemiaAkriti G Jain, Virginia O Volpe, Chen Wang, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 28, 2024
Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and OutcomesLuis E Aguirre, Akriti Jain, Somedeb Ball, et al.
Blood Advances|September 25, 2024
Myeloid clonal hematopoiesis of indeterminate potential in patients with chronic lymphocytic leukemiaAbi Vijenthira, Virginia O Volpe, Aswin Sekar, et al.
Leukemia Research|November 8, 2021
MYC overexpression is associated with an early disease progression from MDS to AMLDavid Gajzer, Constantine N Logothetis, David A Sallman, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemiaEmma-Jayne Minihane, Leah Krotee, Jason Wu, et al.
Pageof 2